All News
Vasculitis Updates: Glucocorticoid use in AAV and GCA
2026 EULAR Press Release
Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs. EULAR has recommendations that cover glucocorticoid use in ANCA associated vasculitides (AAV) and large vessel vasculitis, including giant cell arteritis (GCA).1,2 But the evidence base continues to grow about their use – especially over the long term.
Read Article
⚖️ Does BMI outrank treatment in early PsA outcomes?
YES - SPEED trial AI analysis:
BMI #1 predictor of PASDAS at 1yr in 192pts
#OP0187 #EULAR2026 @RheumNow https://t.co/9cZG7AWau2
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Good news! #Survival in #SLE is improving
#SLR of #lupus publications over time in 233 publications
Bad news - still a mortality gap!
#EULAR2026
@RheumNow @eular_org
ABST#POS0684 https://t.co/PVmQI2duYS
Janet Pope Janetbirdope ( View Tweet)
💉 Does bimekizumab work in real-world PsA?
YES - EuroSpA: 76% retention at 6months
46% DAPSA LDA in 787pts across 12 registries
#OP0185 #EULAR2026 @RheumNow https://t.co/TXS3r9mZXB
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🧲 Does GUS+GOL combo beat GUS alone on MRI in PsA?
YES for joints - AFFINITY Phase 2a RCT: greater MRI inflammation reduction in 91pts
#OP0186 #EULAR2026 @RheumNow https://t.co/9eIS6lh7WN
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Sustained remission in #SLE at 5 yrs w CAR-T
8 severe SLE patients treated with
autologous CD19-CAR T cells
(Zorpocel; Miltenyi Biomedicine)
#antiDNA and #SLEDAI #antiSm ➡️prolonged suppression
Big ? - how long will it work for
Impressive!
@RheumNow #EULAR2026
#EULARbest #729 https://t.co/8iOSImX3w6
Janet Pope Janetbirdope ( View Tweet)
🧬 Do biomarkers predict #zasocitinib response in PsA?
YES: TYK2/IL-17 pathway markers predict ACR20 in 290pts Phase 2b RCT
#OP0184 #EULAR2026 @RheumNow https://t.co/AVlyrauI5q
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔎 Can US predict PsA progression from psoriasis?
YES: synovio-entheseal inflammation predicts progression in 183pts prospective cohort
#OP0183 #EULAR2026 @RheumNow https://t.co/7B9KU60qFd
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Defining the TRM- SLE patient response.
Patient eligibility would be the key
#EULAR2026 @RheumNow https://t.co/5CzQYgc12K
Links:
Bella Mehta bella_mehta ( View Tweet)
🦴 What drives enthesophytes in PsA?
SITE-SPECIFIC:
Pelvic driven by disease activity+BMI
Calcaneal by BMI+damage
in a 1596pts cohort
OP0182 #EULAR2026 @RheumNow https://t.co/4RxgjJ2V9u
Nelly ZIADE 🍀 Nellziade ( View Tweet)
❤️ Do biologics differ in MACE risk in PsA?
YES - JAKi highest risk after 2.5yrs vs TNFi/IL-17i/IL-23i in a retrospective cohort of 22,246pts.
OP0181 #EULAR2026 @RheumNow https://t.co/eQdBtMfRAY
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Treatment for #lupus #brain #fog?!
#small #RCT of Memantine a N-methyl-D-aspartate receptor (NDAR) antagonist used in #Alzheimers
SLE-more permeability in #brain #SLE -antiDNA cross reacting w NDAR
#memantine N=19 v #PBO N=25 showed more improvemt
#EULAR2026 @RheumNow POS701 https://t.co/qvHOy9oDS7
Janet Pope Janetbirdope ( View Tweet)
DESIR Cohort 10-year data (OP0102): SIJ structural lesions in #axSpA progress slowly, but prior MRI bone marrow oedema predicts later structural damage. bDMARD exposure was associated with less erosion progression supporting early biologic treatment Abstr OP0102 @RheumNow
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Male sex independently associated with greater mSASSS increase (β 0.29), higher odds of ≥2-unit mSASSS progression (OR 2.08), and new syndesmophyte formation (OR 1.90) in #axSpA despite lower disease activity scores. Treat symptoms and progression Abstr OP0101 @RheumNow
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
RD in #IBD: 18.6% of 650 IBD pts affected, most commonly peripheral arthritis and AxSpa. Key finding: 14% of rheumatic manifestations preceded IBD diagnosis. Rheumatologists may see these pts first. GI-rheum collaboration is essential. @RheumNow #EULAR2026 POS0807 https://t.co/028yzOxJ2R
Jiha Lee JihaRheum ( View Tweet)
#EULAR2026 POS0079 Phase I study of “Off-the-Shelf” CD19 CAR-T FT819 in N=13 #SLE pts with/-out LN reported favourable efficacy and safety particularly with Bendamustine conditioning. Advantages: scalable and requires minimal or no conditioning. Will move on to Phase II @RheumNow https://t.co/2rt646Qf0T
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Over 10 years in the GESPIC cohort, males with #axSpA had lower ASDAS/BASDAI and enthesitis but double the odds of significant spinal radiographic progression vs females (OR 2.08). Symptoms don’t always correlate to structural damage Abstr OP0101 @RheumNow #EULAR2026
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival at 12m) and axSpA (80% vs 68%), but not RA. Yet 74% of axSpA pts still got another TNFi. Evidence vs practice gap in plain sight. @RheumNow #EULAR2026 POS0776
Jiha Lee JihaRheum ( View Tweet)
JAKi vs ABA in RA-ILD: emulated target trial (n=1,162), JAKi with worse composite respiratory outcomes (HR 1.57) and all-cause mortality (HR 1.59) vs ABA over 5 yrs. JAKi with ↑ pneumonia risk. In RA-ILD, ABA may be the preferred choice? @RheumNow #EULAR2026 POS0813 #EULARBEST
Jiha Lee JihaRheum ( View Tweet)
Real-world bimekizumab in SpA/#PsA (BIMPACT, n=223): 76% retention at 12mo, even with 54% having prior IL-17i exposure. Effective after IL-17Ai failure. Oral candidiasis higher in PsA (16.5%) vs SpA (3.3%); led to discontinuation in ~25%. @RheumNow #EULAR2026 POS0798/POS0810
Jiha Lee JihaRheum ( View Tweet)
